Opus Genetics (IRD) EBIT Margin (2010 - 2026)
Opus Genetics (IRD) reported EBIT Margin of 665.92% for Q1 2026, down 43872.0% year-over-year from N/an in Q1 2025, and down 124.73% quarter-over-quarter from 296.33% in Q4 2025.
Opus Genetics (IRD) EBIT Margin (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 8 years of EBIT Margin data on file, last reported at 665.92% in Q1 2026.
- EBIT Margin for Q1 2026 came in at 665.92%, down 43872.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 359.13% (up 11187.0% YoY), and the FY2025 annual result was 271.9%, up 29282.0% from the prior year.
- EBIT Margin fell to 665.92% in Q1 2026 per IRD's latest filing, from 296.33% in the prior quarter.
- Over five years, EBIT Margin peaked at 85.85% in Q4 2022 and troughed at 883.98% in Q4 2024.
- A 5-year average of 338.42% and a median of 302.67% in 2025 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin slumped 60224 bps in 2024, then soared 58766 bps in 2025.
- A 5-year view of EBIT Margin shows it stood at 85.85% in 2022, then sank by 474 bps to 321.05% in 2023, then tumbled by 175 bps to 883.98% in 2024, then soared by 66 bps to 296.33% in 2025, then tumbled by 125 bps to 665.92% in 2026.
- Business Quant data shows IRD's EBIT Margin at 665.92% in Q1 2026, 296.33% in Q4 2025, and 269.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Opus Genetics | 350.17 Mn | 290.21 Mn | - | -665.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -665.92% |
| Dec 31, 2025 | -296.33% |
| Sep 30, 2025 | -269.93% |
| Jun 30, 2025 | -309.02% |
| Mar 31, 2025 | -227.21% |
| Dec 31, 2024 | -883.98% |
| Sep 30, 2024 | -207.11% |
| Jun 30, 2024 | -748.92% |
| Mar 31, 2024 | -450.50% |
| Dec 31, 2023 | -321.05% |
| Sep 30, 2023 | 53.51% |
| Jun 30, 2023 | -146.68% |
| Mar 31, 2023 | -350.54% |
| Dec 31, 2022 | 85.85% |
| Sep 30, 2021 | -865.44% |
| Jun 30, 2021 | -7,137.00% |
| Mar 31, 2020 | -237.83% |
| Jun 30, 2010 | -17,008.07% |